Inflammatory Breast Cancer: Diagnostic, Molecular and Therapeutic Considerations

AbstractPurpose of ReviewInflammatory breast cancer (IBC) is an aggressive type of breast cancer with poor prognosis. Treatment for non-metastatic disease is neoadjuvant chemotherapy followed by mastectomy and radiation. IBC diagnosis is primarily a clinical diagnosis, which can lead to misdiagnosis and delayed management. In addition, there are no molecular criteria for diagnosis or therapeutic regimens developed specifically for IBC. We aimed to discuss recent developments in IBC, including diagnosis, molecular mechanisms, and treatment.Recent FindingsRecently, the Union for International Cancer Control (UICC) and the American Joint Committee on Cancer (AJCC) breast cancer staging system has defined the diagnostic features of IBC. Current molecular characterization of IBC has not revealed a unique signature or marker for diagnosis; however, this work sheds light on the pathophysiology of IBC and provides potential therapeutic targets.SummaryThe prognosis of IBC remains poor, although the survival is improved significantly with trimodal management. To date, a consensus on diagnosis and prospective trials specifically designed for IBC therapy are lacking. Standardized criteria incorporating clinical, pathologic, and molecular criteria remains an unmet need. Recent consensus recommendations regarding diagnosis and management are reviewed with a view towards evolving molecular characterization, potential targets, and current clinical trials.
Source: Current Breast Cancer Reports - Category: Cancer & Oncology Source Type: research

Related Links:

m Stéphane Brézillon Glycosaminoglycans (GAGs)/proteoglycans (PGs) play a pivotal role in the metastasis of inflammatory breast cancer (IBC). They represent biomarkers and targets in diagnosis and treatment of different cancers including breast cancer. Thus, GAGs/PGs could represent potential prognostic/diagnostic biomarkers for IBC. In the present study, non-IBC MDA-MB-231, MCF7, SKBR3 cells and IBC SUM149 cells, as well as their GAG secretome were analyzed. The latter was measured in toto as dried drops with high-throughput (HT) Fourier Transform InfraRed (FTIR) spectroscopy and imaging. FTIR imaging ...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
rveriat Marc Espié Anne De Roquancourt Anne-Sophie Hamy Sylvie Giacchetti Inflammatory breast cancers are very aggressive, and among them, triple negative breast cancer (TNBC) has the worst prognosis. While many studies have investigated the association between tumor-infiltrating lymphocytes (TIL) before neoadjuvant chemotherapy (NAC) and outcome in TNBC, the impact of post-NAC TIL and TIL variation in triple negative inflammatory breast cancer (TNIBC) outcome is unknown. Between January 2010 to December 2018, all patients with TNIBC seen at the breast disease unit (Saint-Louis Hospital) were treated wit...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Inflammatory breast cancer (IBC) is a rare and aggressive form of breast cancer, accounting for only 1-5% of breast cancer diagnoses but up to 10% of breast cancer deaths annually in the United States. In contrast to findings in non-IBC patients, prior studies of stage III IBC patients suggest that compared to other receptor subtypes, hormone receptor (HR) positivity is not a favorable prognostic factor.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
CONCLUSION: Our study provides novel insight into clinicopathological characteristics and treatment status among patients with IBC in China, and might provide a direction and basis for further studies. TRIAL REGISTRATION: chictr.org.cn, No. ChiCTR1900027179; http://www.chictr.org.cn/showprojen.aspx?proj=45030. PMID: 32925286 [PubMed - as supplied by publisher]
Source: Chinese Medical Journal - Category: General Medicine Authors: Tags: Chin Med J (Engl) Source Type: research
ConclusionsWe identified novel risk factors for IBC and non-IBC, some of which preferentially increased risk of IBC compared to non-IBC. Upon confirmation, these findings could help illuminate the etiology and aid in prevention of this aggressive cancer.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Naoto T. Ueno Inflammatory breast cancer (IBC), although rare, is the most aggressive type of breast cancer. Only 2–4% of breast cancer cases are classified as IBC, but—owing to its high rate of metastasis and poor prognosis—8% to 10% of breast cancer-related mortality occur in patients with IBC. Currently, IBC-specific targeted therapies are not available, and there is a critical need for novel therapies derived via understanding novel targets. In this review, we summarize the biological functions of critical signaling pathways in the progression of IBC and the preclinical and clinical st...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Publication date: Available online 29 August 2020Source: Journal of Advanced ResearchAuthor(s): Sudpreeda Chainitikun, Sadia Saleem, Bora Lim, Vicente Valero, Naoto T. Ueno
Source: Journal of Advanced Research - Category: Research Source Type: research
eifan Zheng Drug repurposing is an effective means for rapid drug discovery. The aim of this study was to develop and validate a computational methodology based on Literature-Wide Association Studies (LWAS) of PubMed to repurpose existing drugs for a rare inflammatory breast cancer (IBC). We have developed a methodology that conducted LWAS based on the text mining technology Word2Vec. 3.80 million “cancer”-related PubMed abstracts were processed as the corpus for Word2Vec to derive vector representation of biological concepts. These vectors for drugs and diseases served as the foundation for creatin...
Source: Molecules - Category: Chemistry Authors: Tags: Article Source Type: research
Authors: Linhares S, Alrammah T, Alghamdi HA, Möller MG Abstract Inflammatory breast cancer (IBC) represents only 1% to 5% of all breast malignancies and is an extremely aggressive subtype. At time of diagnosis, up to 85% of patients will present with regional nodal metastases and up to 30 % will have metastasis to distant organs. There is limited medical literature describing treatment guidelines for IBC during gestation. The best diagnostic tools are core needle and full-thickness skin punch biopsies to assess presence of dermal lymphatic invasion. Breast Ultrasound is preferred to mammogram, but mammography...
Source: Advances in Experimental Medicine and Biology - Category: Research Tags: Adv Exp Med Biol Source Type: research
Publication date: Available online 19 August 2020Source: Journal of Advanced ResearchAuthor(s): F. Lerebours, S. Vacher, J.M. Guinebretiere, S. Rondeau, M. Caly, D. Gentien, S. Van Laere, F. Bertucci, P. de la Grange, l. Bièche, X. Liang, C. Callens
Source: Journal of Advanced Research - Category: Research Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Inflammatory Breast Cancer | Mastectomy | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Radiation Therapy | Neoadjuvant Therapy